Compare InMode Ltd (INMD) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Novartis AG — how do they compare? InMode Ltd trades at $15.16 (market cap $872.08M), while Novartis AG trades at $152.33 (market cap $295.37B). The key difference: Novartis AG is far larger — about 338.7× InMode Ltd's market cap, and Novartis AG pays a 3.07% dividend while InMode Ltd pays none. Which is the better fit depends on your goals.
| INMD | NVS | |
|---|---|---|
Market Cap | $872.08M | $295.37B |
Sector | Technology | Health |
52-Week High | $16.62 | $168.62 |
52-Week Low | $12.76 | $119.31 |
Enterprise Value | $375.42M | $336.69B |
Dividend Yield | — | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
InMode (INMD) trades at $15.31, up 1.26% with a bullish technical outlook. The stock shows strong profitability with 76.52% gross margins and 20.69% net income margin, though 2026 earnings guidance suggests margin compression. Recent developments include an unsolicited acquisition offer from Steel Partners at $16.75 per share and ongoing shareholder activism. Technical indicators show bullish moving averages with neutral oscillators, while analyst consensus is divided between Buy and Hold ratings.
The investment case balances attractive valuation metrics (P/E 12.55, EV/EBITDA 5.39) against execution risks and shareholder disputes. Near-term catalysts include the Q3 2026 earnings report and potential acquisition developments. Key risks involve competitive pressures in medical aesthetics and ongoing securities investigations that could impact investor confidence.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
